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Abstract
Objectives: To describe CSF-defined neuronal intermediate filament (NIF)
autoimmunity. Methods: NIF-IgG CSF-positive patients (41, 0.03% of 118599
tested, 1996–2019) were included (serum was neither sensitive nor specific).
Criteria-based patient NIF-IgG staining of brain and myenteric NIFs was
detected by indirect immunofluorescence assay (IFA); NIF-specificity was con-
firmed by cell-based assays (CBAs, alpha internexin, neurofilament light [NF-
L]), heavy-[NF-H] chain). Results: Sixty-one percent of 41 patients were men,
median age, 61 years (range, 21–88). Syndromes were encephalopathy predomi-
nant (23), cerebellar ataxia predominant (11), or myeloradiculoneuropathies
(7). MRI abnormalities (T2 hyperintensities of brain, spinal cord white matter
tracts. and peripheral nerve axons) and neurophysiologic testing (EEG, EMG,
evoked potentials) co-localized with clinical neurological phenotypes (multifocal
in 29%). Thirty patients (73%) had ≥ 1 immunological perturbation: cancer
(paraneoplastic), 22; systemic infection (parainfectious [including ehrlichosis, 3]
or HIV), 7; checkpoint-inhibitor cancer immunotherapy, 4; other, 5. Cancers
were as follows: neuroendocrine-lineage carcinomas, 12 (small cell, 6; Merkel
cell, 5; pancreatic, 1 [11/12 had NF-L-IgG detected, versus 8/29 others,
P = 0.0005]) and other, 11. Onset was predominantly subacute (92%) and
accompanied by inflammatory CSF (75%), and immunotherapy response
(77%). In contrast, CSF controls (15684 total) demonstrated NIF-IgG negativity
(100% of test validation controls), and low frequencies of autoimmune diag-
noses (20% of consecutively referred clinical specimens) and neuroendocrine-
lineage carcinoma diagnosis (3.1% vs. 30% of NIF cases), P < 0.0001. Median
NF-L protein concentration was higher in 8 NF-L-IgG-positive patients (me-
dian, 6718 ng/L) than 16 controls. Interpretation: Neurological autoimmunity,
defined by CSF-detected NIF-IgGs, represents a continuum of treatable axono-
pathies, sometimes paraneoplastic or parainfectious.
Introduction
Several proteins with prominent structural integrity roles
in neurons and glia have been reported as substrates for
neurological autoimmunity, including the axon-abundant
neuronal intermediate filaments (NIFs).1-4 NIF-IgGs from
affected patients produce either of two criteria-based pat-
terns of IgG binding to neuronal filamentous elements on
murine tissue-based indirect immunofluorescence assay
(IFA).1 For neurological diagnosis, a testing algorithm
that included alpha internexin (aIN, which is not a neu-
rofilament), neurofilament light chain (NF-L), and heavy
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chain (NF-H)-IgGs have proven sufficient for confirma-
tion of tissue findings and clinical interpretation. An anti-
body profile that included NF-L-IgG positivity was
associated with paraneoplastic CNS disorders accompa-
nied by neuroendocrine-lineage carcinomas, most com-
monly Merkel cell or small cell type.1 Clinical significance
remained uncertain in patients with other NF-L-IgG-neg-
ative profiles, many of whom were historical cases with
only serum and limited clinical data available. A parain-
fectious cause in some patients also appears plausible, as
we have previously identified some cases of ehrlichosis
preceding neurological symptom onset.
Herein, we describe in detail our entire clinical experi-




Patients were all those (both Mayo Clinic and external
referrals) in whom NIF-IgGs were detected in CSF in the
Neuroimmunology Laboratory (NIL) of the Mayo Clinic
in the course of clinical service evaluation for autoim-
mune neurological disorders. Testing was undertaken by a
two-step algorithm, as described previously.1 First, all
specimens were screened for NIF-IgGs by IFA, and met
criteria for either pattern 1 (typical of NF-L, or aIN-pre-
dominant IgG staining) or pattern 2 (typical of NF-H-
predominant IgG staining), Figure 1, left panels. Second,
all positive specimens yielded by the first step were tested
Figure 1. NIF-IgG studies in CSF. Left panels, A-E, patterns of NIF-IgG staining of mouse tissue by indirect immunofluorescence. A, pattern 1
(aIN- or NF-L-predominant); staining throughout the cerebellum with prominent blush in the molecular layer (left). B, pattern 2 (NF-H-
predominant); staining is mostly restricted to the granular layer (right) and Purkinje cell layer (middle), with sparse molecular layer staining (left).
Staining of other elements, such as white matter (C, asterisks), myenteric plexus (D), and hippocampus (E), are identical for patterns 1 and 2.
Right, HEK-293 cell-based assay confirming positivity for all three NIF-IgG subtypes evaluated in a patient whose CSF produced pattern 1 NIF-IgG
staining by the tissue-based assay.
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by three NIF-specific CBAs (aIN, NF-L, and NF-H), and
were positive in at least one of those assays, Figure 1,
right panels. Forty-one such CSF-positive cases were
acquired consecutively between October 30th 1996 and
June 30th 2020 (of 118599 patients who had CSF tested in
the course of assessment for autoimmune neurological
diagnoses, 0.03%). An additional 80 cases with serum
NIF-IgG positivity were also acquired over that time
frame and were excluded from this study (77 had no
available CSF to evaluate further; all 3 for whom CSF was
available, but were NIF-IgG negative, had alternative non-
autoimmune diagnoses [frontotemporal dementia, classi-
cal multiple sclerosis, or metabolic encephalopathy]).
Clinical and testing data were obtained from the Mayo
Clinic electronic medical record (13) and outside neurol-
ogists (28) by CZ, SS, and AM. MRI images were
reviewed and selected by AM, EF, and DD (CNS), and
AAM (peripheral nervous system).
Ehrlichia chaffeensis testing
Each specimen was diluted (serum, 1:64; CSF 1:2) and
placed in microscopic slide wells precoated with Ehrlichia
chaffeenis-infected cells. After incubation, the slides were
washed and a fluorescein-isothiocyanate conjugate was
added to each well. The slides were then read using a flu-
orescence microscope. Fluorescent staining of intracellular
organisms constituted a positive result.
Controls
The following CSF control cohorts were evaluated:
1 Laboratory analytical: from 70 patients without autoim-
mune CNS disease (50 adult; 20 pediatric) assayed in
the course of test verification procedure to meet regula-
tory requirement for clinical use.
2 Clinical neurological: 120 consecutive Mayo Clinic
Rochester patients (3:1 ratio with cases) evaluated in
the Department of Neurology who had CSF tested in
NIL during 2019.
3 Clinical cancer: All 15494 Mayo Clinic patients with
CSF sent to NIL for neural autoantibody evaluation
(1996–2018). Patient records were cross-referenced for
cancer diagnoses (historical or contemporary) pertinent
to the patient results (neuroendocrine-lineage carcino-
mas [small cell, Merkel cell, other] and lymphomas
[Hodgkin and non-Hodgkin type, not including those
with CNS lymphoma).
4 Measurement of CSF NF-L protein concentration: CSF
specimens were from 8 of the NIF autoimmune cohort
(all NF-L-IgG positive), 8 patients with multiple sclero-
sis (MS), and 8 patients with normal pressure hydro-
cephalus (NPH). Measurement of CSF NF-L protein
concentration was performed in duplicates by investiga-
tors blinded to clinical data using a commercially avail-
able enzyme-linked immunosorbent assay (NF-light;
Uman Diagnostics, Umea, Sweden) as described by the
manufacturer with the same batch of reagents.
Statistical analysis
Comparisons of categorical variables pertinent to NIF
autoimmune patients and controls were undertaken uti-
lizing Chi-square test with Yates correction and Fisher
exact test as appropriate.
Results
All 70 CSF analytical controls were negative by tissue IFA,
and all 3 NIF CBAs (aIN, NF-L, and NF-H), testing
undertaken in the course of test verification and valida-
tion for clinical use in our diagnostic laboratory. All 41
included patient CSF specimens that met diagnostic NIF-
IgG immunohistochemical criteria, had ≥ 1 NIF-IgGs
detected by CBAs: aIN (29); NF-H (30); and NF-L (20).
CSF from 14 patients (9 had NF-H-IgG positivity alone
by CBAs) produced pattern 2 (heavy-chain typical) stain-
ing by IFA, and the remaining CSF from 27 patients pro-
duced pattern 1 staining (none had NF-H-IgG positivity
alone), Figure 1. Companion serum was available in 27 of
41 patients, and was NIF-IgG negative in 20 (74%).
Demographic and neurological phenotypes
Thirteen patients were evaluated neurologically at the
Mayo Clinic. Twenty-five patients were male (61%). Med-
ian age at CSF testing was 61 years (range, 21–88),
Tables 1–3. Twenty-one patients were previously reported,
and are clinically described in further detail herein, along
with the remaining 20 patients acquired 2018–2020. Neu-
rological presentations were subacute over a course of 0-
3 months in 36 patients (90%), with a progressive course
over 3–6 months in the other 4. Four patients were
known to have a relapsing course.
Neurological phenotypes among 120 neurological con-
trols consecutively referred to the Neuroimmunology Lab-
oratory for CSF antibody testing (all NIF-IgG negative)
were diverse. Twenty-four (20%) had final clinical
autoimmune or other inflammatory diagnoses: encephali-
tis, 14; neuropathy, 3 (all large fiber [axonal, 2; demyeli-
nating, 1]); ataxia, 2; MS, 2; neuromyelitis optica, 1;
myelitis, 1; stiff-person syndrome, 1. The remaining 96
controls (80%) had: psychiatric disorders, 22; unspecified
neurological disorders, 17 (cognitive, 12; ataxia, 1; periph-
eral nervous/autonomic, 4); degenerative dementias, 17;
primary headache disorders, 15; metabolic
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encephalopathies, 7; stroke, 5; primary seizure disorders,
5; other non-neurologic, 5; brain neoplasms, 2; and
hereditary, 1.
In contrast, NIF autoimmune phenotypes were
restricted to three groups (Tables 1–3): encephalopathy
predominant, 23 (56%); ataxia predominant, 11 (29%);
and myelopolyradiculoneuropathy, 7 (15%). Twelve
patients had multifocal neurological disease (29%). In
contrast with controls, 31 of 41 NIF-IgG cases (77%,
including all 13 Mayo Clinic cases) had documentation
supportive of nervous system inflammation: ≥1 of
increased post-gadolinium enhancement on MRI,
increased white cells or oligoclonal bands in CSF, or pre-
viously characterized neural IgG detected in serum or
CSF, Tables 1–3, P < 0.0001, Fisher Exact Test.
The 23 patients with the most common phenotype,
encephalopathy predominant, had rapid onset and pro-
gression of cognitive impairment, typically multimodal.
All had rapid onset delirium and memory problems, and
one or more additional features: vision disturbance (6: 5
had blurred vision without ophthalmologic findings,
including 2 with hemianopsia; 1 had ophthalmitis and
coexisting CRMP-5-IgG), motor apraxia (4, [of gait, 4, of
eyelids, 1]), headache (5, 3 had meningism), mood
change (4), seizures (3, [generalized, 2; focal dyscognitive,
1]), or language disorder and dyskinesias (1, and coexist-
ing NMDA-R antibody). Eleven had ≥ 1 accompanying
signs of brainstem dysfunction (8: dysarthria, 6; dyspha-
gia, 4; diplopia, 2; nausea, 1; facial palsy, 1; tremor, 1;
ptosis and bulbar palsy, 1), myelopathy (4), cerebellar
ataxia (3), and polyradiculoneuropathy (1). Detailed neu-
ropsychometric testing in Patient 14 revealed deep white
matter localization (moderate global cognitive deficits,
with executive dysfunction particularly notable, localizing
to frontal and subcortical pathways).
A cerebellar or brainstem predominant neurological
phenotype was encountered in 11 patients (30%), 4 of
whom also had myelopathic findings (Table 2). Addi-
tional brainstem findings included: diplopia, 4; vertigo, 2;
vomiting, 2; and dysarthria, 2.
The remaining 7 patients (18%) had, as the sole neuro-
logical manifestation: inflammatory lumbosacral
polyradiculopathies (3), myelitis (2), myeloneuropathy
(1), and multifocal motor neuropathy with conduction
block (GM-1 antibody negative, 1), Table 3. Among 15
total patients with myelopathic or neuropathic findings, 8
had considerable limb or generalized body pain at onset
(Tables 1–3).
MRI findings
Data were available in 36 patients (88%). Twelve of 36
patients (35%) were reported to have normal imaging, all
evaluated outside Mayo Clinic. A further four had normal
brain imaging initially, which subsequently demonstrated
deep white matter T2 hyperintensities. Among the 16
non-Mayo cases with abnormal imaging, T2 abnormalities
were reported in ≥ 1 of hemispheric deep white matter
(6, with accompanying enhancement in 3, including 1
with radial periventricular enhancement, and coexisting
GFAP-IgG), brainstem (4), cerebellum, (3) and spinal
cord (3, with accompanying enhancement in 2).
MR images were reviewed in detail for 13 Mayo Clinic
patients; all had abnormalities detected (Figures 2 and 3,
Tables 1–3). Observed brain abnormalities were conflu-
ent, hazy T2 change in white matter of ≥ 1 of cerebral
periventricular deep white matter (7), brainstem (2), tem-
poral lobes (1), and cerebellum (1). Although individually
nonspecific in appearance (and generally reported as such
by radiology), those changes were neurological localiza-
tion-relevant throughout the group (Tables 1 and 2).
Post-gadolinium enhancement was also observed in
Patient 14 (periventricular radial and leptomeningeal
radial [GFAP-IgG negative]) and patient 20 (left facial
nerve). One patient with severe pancerebellar ataxia (27)
had initial normal imaging, but diffuse cerebellar atrophy
at follow-up. Patient 12, with shoulder pain after
encephalitis onset, also had thickening and increased T2
signal of brachial plexus, without enhancement (Fig-
ure 3). Three patients with myelopathy (1) or
encephalomyelopathy (2) had longitudinally extensive T2
signal change in the cord (dorsal cord and white matter
tract predominant, hazy in 2, with accompanying dorsal
cord-predominant postgadolinium enhancement in 1),
Figure 2. Patient 38 with myeloneuropathy had short seg-
ment dorsal thoracic T2 signal change, thickened and T2
hyperintense lumbosacral roots, and T2 hyperintensity of
bilateral femoral nerves. Both patients 16 (encephalopathy
and asymptomatic polyradiculoneuropathy detected on
EMG) and 40 (symptomatic polyradiculoneuropathy) had
enhancement of the anterior thecal sac and nerve roots.
Neurophysiology
EEG was abnormal in 4 of 6 patients with encephalopathy
(generalized diffuse delta slowing in all, with superim-
posed electrographic seizures in 2), Table 1. EMG
revealed lumbosacral polyradiculoneuropathy (2), axonal
sensorimotor neuropathy (2), and multifocal motor neu-
ropathy with conduction block (1). Two patients evalu-
ated at Mayo Clinic had spinal cord localizing slowing of
central proprioceptive pathways on somatosensory-evoked
potentials (both had MRI T2 cord lesions). Electrophysio-
logical testing in Patient 38 (Table 3, with hearing loss,
right face pain, and diffuse truncal and limb pain)
revealed right sensorineural hearing loss by audiogram,
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absent right blink response, slowing of central proprio-
ceptive, and sensorimotor axonal neuropathy on EMG.
All 13 patients evaluated at Mayo Clinic had normal
metabolic laboratory test results including vitamin B12,
methylmalonic acid, and folate.
Oncological and immunological findings
In total, 30 patients (73%) had ≥ 1 documented risk fac-
tor for neurological autoimmunity: contemporaneous
cancer (paraneoplastic), 22; contemporaneous preceding
respiratory infection (post-infectious), 5; checkpoint inhi-
bitor cancer immunotherapy, 4; coexisting autoimmune
disease, 5; and long-standing HIV, 2, (Tables 1–3).
Contemporaneous cancer diagnoses (within 24 months
of neurological symptom onset) were made in 22 patients
(54%), and 13 after onset of neurological symptoms.
These cancers were as follows: carcinoma of neuroen-
docrine lineage (12: SCLC, 6; Merkel cell, 5; pancreatic,
1), adenocarcinomas, (3: lung, 2; metastatic prostate, 1),
systemic lymphoma (3: non-Hodgkin, 2; Hodgkin, 1),
hepatocellular carcinoma, 2; papillary cell renal carci-
noma, 1; and leiomyosarcoma, 1.
NF-L-IgG was detected in 11 of 12 patients with neu-
roendocrine-lineage carcinomas, and in 8 of 29 other
patients (P = 0.0005), Fisher Exact Test, Tables 1–3. Indi-
vidual NIF-IgGs served to confirm the overall diagnosis,
but were not otherwise predictive of neurological
Figure 2. MRI brain findings. Images are all axial T2 FLAIR except: last panel right, top row (T1 sagittal); second-to-last and last right panels, 2nd
row, and last panel, right, 3rd row (T1 axial postgadolinium). Clinical localization-related hazy-appearing T2 white matter hyperintensities were
observed in deep white matter of cerebral hemispheres in patients 2, 3, 12, 14, 19, 20, 23, and 34 (Tables 1 & 3), and pontine white matter in
patients 20 and 34. Patient 14 also had postgadolinium enhancement (linear radial, left; and leptomeningeal, right [GFAP-IgG negative]). Patient
28 had cerebellar atrophy at follow-up. Patient 34 also had enhancement of the left facial nerve (arrow).
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phenotype or cancer (P > 0.05). All three patients with
lymphoma had NF-H-IgG positivity only. The cancer
control cohort of 15494 patients revealed 478 had small
cell carcinoma or other neuroendocrine-lineage carcinoma
(3.1%), and 432 had lymphoma (2.8%). Neuroendocrine
lineage carcinomas were more common among the NIF-
IgG cohort (12/40, 30%) than the control group (chi-
square, 86.4, P < 0.0001); no statistical difference was
observed for lymphoma (chi-squared, 1.52, P = 0.185).
Five further patients developed neurological symptoms
during recovery from systemic infections; ehrlichosis in 3
and undocumented pathogen in 2. Patient 16, evaluated
in detail at Mayo Clinic (Table 1) developed diffuse body
pain and neck ache, followed by encephalopathy and
inflammatory CSF, 2 weeks after a tick bite. She had lab-
oratory findings typical of systemic ehrlichosis, without
evidence of CNS disease. She had elevated ALT (236 U/L,
normal value, 7-45) and thrombocytopenia (58/lL; nor-
mal value, 157-371) on hospital admission; both values
normalized over the course of her 10-day hospitalization.
Ehlichia chaffeensis testing revealed: PCR, serum positive,
CSF negative; IgG, serum positive (1:2048; nor-
mal < 1:64), and CSF positive (1:32; normal, <1:2) with
no cross-reactivity detected for other ehrlichia forms,
anaplasmosis, or Lyme disease. She was treated with
doxycycline for 3 weeks. Her encephalopathy gradually
resolved to near normal over the course of 8 weeks, with-
out further intervention. Ehrlichia chaffeensis IgG testing
was undertaken in a further 10 patients with available
serum (6 with cancer, 4 without), all were negative.
Among the 9 patients who developed cancer prior to
neurological symptom onset, 4 had been treated with
Figure 3. MRI spine and nerve findings. MRI spine, sagittal, top row; axial, bottom row, except right-most column, which are all axial T2 images.
Lumbosacral spine, T1 postgadolinium images in patients 16 (asymptomatic EMG-documented lumbosacral polyradiculoneuropathy and
encephalopathy [Figure 2]) and 40 (symptomatic lumbosacral polyradiculoneuropathy) reveal enhancement of anterior thecal sac (top, arrow
heads) and nerve roots (bottom). Patients 20, 34, and 35 with myelopathy had dorsal cord white matter predominant longitudinally extensive T2
hyperintensities, hazy-appearing in patients 20 and 34, with cord expansion and enhancement in patient 35. Axial cord images reveal T2
hyperintensities and T1 postgadolinium to be white matter tract predominant. Patient 38 with myeloneuropathy had T2 hyperintensity of right-
sided white matter tract in the thoracic cord (top), T2 signal change and enlargement of lumbosacral nerve roots (middle top), and T2
hyperintensity of bilateral femoral nerves (right-side demonstrated, middle bottom, arrow head). Patient 12 with encephalopathy (Figure 2) and
bilateral shoulder pain had T2 hyperintensity of the brachial plexus (bottom, circled).
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immune checkpoint inhibitors (pembrolizumab, 3; ipili-
mumab and nivolumab, 1). These four patients were
being treated for Merkel cell carcinoma (3) or lung ade-
nocarcinoma (1). Coexisting medical disorders indicative
of background immune dysregulation prior to neurologi-
cal symptom onset were present in 7 patients (rheuma-
toid arthritis, 3; HIV, 2 [1 with CD4 count > 400; 1
noncompliant with antiretroviral medication]; pernicious
anemia, 1; autoimmune thyroiditis, 1; membranous
glomerulonephritis, 1).
Additional CSF findings
Routine CSF data were available in 28 patients (74%,
Tables 1–3), and was inflammatory (at least one of white
cell count or oligoclonal bands elevated) in 21 of those
(75%). CSF protein was elevated in all patients tested
(median value, 71 mg/dL [range, 41–150 mg/dL; normal,
≤35]). White cell count was elevated in 20 patients (71%:
median value, 16/lL [range, 8-199; normal, ≤ 5]), all lym-
phocyte predominant. CSF-exclusive supernumerary
oligoclonal band numbers were elevated in 14 patients
(50%: median value, 5 [range, 4–9; normal, <4]). Two of
those 14 patients had elevated IgG index in addition.
Coexisting IgG antibodies
Six patients, including five with cancer (neuroendocrine-
lineage, 4), had coexisting IgGs detected; 2 in CSF, and 4 in
serum (15%), Tables 1 and 2. In CSF, one patient each had
either NMDA-R-IgG (a woman in her 40s with typical
anti-NMDA-R encephalitis phenotype, and accompanying
small cell carcinoma) or GFAP-IgG (typical autoimmune
GFAP astrocytopathy phenotype without cancer). In
serum, one patient with Merkel cell carcinoma had coexist-
ing CRMP-5-IgG (1:15360; normal, ≤240; typical CRMP-5
ophthalmitis, in addition to encephalopathy). The remain-
ing three patients had ataxia in the context of high-titer
GAD65-IgG (397 nmol/L; normal, ≤0.02), ANNA-3
(1:3840; normal, ≤240), or Zic4 antibody; all had cancer.
NF-L protein values
CSF NF-L protein values were higher among patients with
NF-L-IgG (median, 6718 ng/L; range, 165-10000) in com-
parison to age-matched controls with MS at onset (me-
dian, 940 ng/L; range, 426-8166) and NPH (median,
959 ng/L; range, 734–9929), Figure 4.
Treatment and outcome
Median duration of follow-up was 9 months (range, 1–
36). Treatment or outcome data were available for 31
patients (Table 4). Nineteen patients received ≥ 1 neuro-
logical symptom-directed immune therapy in diverse
combinations (≥1 of corticosteroids [15], rituximab [7],
IVIg [4], plasma exchange [3], cyclophosphamide [2],
cancer chemotherapy [2], and azathioprine [1]). Of those
19 patients, 13 (77%) responded neurologically (improve-
ment, 8 or complete remission 5), 1 did not improve,
and 4 worsened. Of 12 patients who had no neurological
attack-related treatment (including Patient 23 who had a
subsequent attack treated), 6 had spontaneous improve-
ment, and 6 worsened. Seven patients were reported to
have died, including 3 who died from cancer and 4 who
died from progression of neurological disease (3 of those
4 were untreated). Of those 11 who worsened or died, 4
had cancer, 3 had a background of infection (none with
ehrlichosis), and 4 had no etiology established (Table 4).
Three of four who developed neurological symptoms in
the context of checkpoint inhibitor cancer treatment
responded to immunotherapy, and one died.
Discussion
CSF-detected NIF autoimmunity unifies patients with
subacute onset, treatable inflammatory neurological disor-
ders, usually affecting the CNS, with a paraneoplastic
cause in over half, and other documented contemporary
immunological perturbation in another fifth. Autoim-
mune encephalopathy and ataxia-predominant brainstem
disorders were most common, and the remainder had
myelopathy or inflammatory polyradiculoneuropathy (in-
cluding 1 patient with the established autoimmune phe-
notype, multifocal motor neuropathy). This is distinct
from the broader profile of phenotypes encountered in
patients referred to our laboratory, and have autoimmune
diagnoses, exemplified by the control group (which also
included neuromyelitis optica, transverse myelitis, and
stiff-person syndrome). The NIF-IgG profiles by cell-
based assay (one or more of aIN-, NF-L-, NF-H-IgGs)
provided confirmation of NIF specificity and prediction
of cancer type (small cell or Merkel cell when NF-L-IgG
was detected), although not specific neurological pheno-
types. NIFs are cytoplasmic proteins, and thus, the anti-
bodies are likely nonpathogenic biomarkers of NIF-
directed T-cell effectors.
In keeping with the diffuse localization of NIF antigens,
one quarter had overlapping neurological phenotypes,
previously observed in patients with autoimmunity target-
ing GFAP, the astrocyte abundant intermediate filament.5
White matter-predominant radiological findings and elec-
trophysiological abnormalities (EEG, audiology blink
reflexes, SSEPs, EMG) from 13 patients studied in detail
at Mayo Clinic support the concept of a continuum of
dysfunction, sometimes spanning both central and
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peripheral nervous systems. Some findings, such as abnor-
mal white matter on MRI and reduced nerve conduction
amplitudes, support the concept of axonal dysfunction in
the context of NIF-directed autoimmunity. Although the
NIF autoimmune neurological presentations were not
uniform, they were distinct from the profile of cases gen-
erally referred to our laboratory for CSF evaluation, 80%
of whom had neurological autoimmunity as initial differ-
ential diagnostic consideration, but ultimately proved to
have other diagnoses.
Radiological abnormalities, on a case-by-case basis,
were often hazy appearing mostly without postgadolinium
enhancement. These abnormalities of white matter in
cerebral hemispheres, pons, cerebellum, and spinal cord,
and nerve roots and peripheral nerves, correlated with the
neurological localization, although did not have specifying
features. The expression of all three proteins studied (NF-
H, NF-L, and aIN) is abundant in the pons and brain-
stem as well as the cerebral white matter, cerebellum, and
to various degrees in the hippocampus, midbrain, spinal
cord (https://www.proteinatlas.org/), and the peripheral
nervous system. There are inter-protein differences in
expression outside the nervous system (https://www.prote
inatlas.org/).6
A paraneoplastic cause was found in just over half of
our patients, which is within the typical 50-80% cancer
detection frequency in classical paraneoplastic neurologi-
cal disorders.7 Small cell carcinoma and other related
neuroendocrine-lineage carcinomas, including Merkel cell,
were most common, and had a strong association in gen-
eral with NIF autoimmunity, in particular with NF-L-
IgG, a protein known to be abundantly expressed in these
tumors.18-10 NF-H-IgG may also have some biological sig-
nificance in lymphoma, although numbers were small and
any paraneoplastic association was not borne out by sta-
tistical analysis, and neoplastic tissue was not available for
further study. All three lymphomas and the one prostate
adenocarcinoma detected were among nine patients (7
Figure 4. CSF NF-L protein concentration comparison between patients with NF-L-IgG and controls. Higher NF-L values indicative of more
pronounced axonal damage were detected in the CSF of patients with NF-L-IgG in comparison with age-matched MS cases and patients with
NPH included as controls.
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men) positive for NF-H-IgG only. NF-H protein is abun-
dant in male prostate, female ovary, colon, adipose and
soft tissue, monocytes and T cells, and is also known to
be expressed in different cancers, including some identi-
fied in this cohort (neuroendocrine carcinoma [Merkel,
pancreatic, SCLC], and prostate adenocarcinoma)
(https://www.proteinatlas.org/).1,8,9,11
We previously reported a patient with paraneoplastic
cerebellar ataxia in the setting of Merkel cell carcinoma,
whose NIF-IgG profile (aIN, NF-L, NF-M, and NF-H, but
not peripherin) matched the NIF protein expression profile
in her biopsied neoplasm.1 These observations support an
onconeural antigen-driven immune response in the parane-
oplastic NIF cases. While the etiology (in some) and the
pathophysiology (in all) of NIF autoimmunity remain to
be elucidated, the rarity of detection of NIF-IgGs in our ref-
erence laboratory (41 cases in 24 years) argues against them
being epiphenomenal byproducts of neurodegeneration.
Table 4. Treatments and outcomes
Pt no. Age/Gender
Neurological syndrome, cancer, or other
potential trigger
Treatment (time to treatment,
months) Outcome
1. M/77 Encephalopathy, URI None Died
2. F/47* Encephalopathy, SCLC Steroids, rituximab, azathioprine (1) Resolved
3. M/52* Encephalopathy Steroids, IVIg (3) Worsened
4. F/74* Encephalopathy, Merkel cell Steroids, IVIG, Rituximab,
cyclophosphamide (6)
Improved
7. M/41 Encephalopathy, enterovirus None Died
8. F/66 Encephalopathy, HIV None Died
10. M/55 Encephalopathy Steroids Improved
11. M/47 Encephalopathy, ehrlichosis None Spontaneous improvement
12. M/63* Encephalopathy, papillary renal cell
carcinoma
Rituximab, steroids (3) Resolved
13. F/75 Encephalopathy & ataxia, Merkel cell Steroids Improved
14. F/60* Encephalopathy IVIg, Steroids, Rituximab (4) Worsened, died
15. M/79 Encephalopathy, hepatocellular carcinoma None Died**
16. F/73* Encephalopathy, ehrlichosis None Spontaneous resolution
17. M/69 Encephalopathy PLEX, steroids, and rituximab Worsened
18. F/43 Encephalopathy & ataxia, HIV None Spontaneous resolution
19. M/88* Encephalopathy & ataxia, pancreas
neuroendocrine
None Died**
21. F/48* Encephalomyelopathy Steroids Resolved
22. M/57 Encephalomyelopathy, lung rhabdoid
adenocarcinoma
Steroids Resolved
23. M/21 Encephalomyelopathy Attack 1: None;
Attack 2: steroids (1)
Resolved on both occasions
24. F/81 Ataxia, Hodgkin lymphoma Chemotherapy Improved
26. F/74 Ataxia, Merkel cell Rituximab Worsened, died**
27. M/64 Ataxia, SCLC IVIg Improved
28. F/74* Ataxia, Merkel cell Steroids, Rituximab,
cyclophosphamide (1)
Improved, but profound disability
(walker or wheelchair)
29. M/65 Ataxia, Merkel cell carcinoma Steroids, Chemotherapy Improved
30. M/64 Ataxia, SCLC Steroids Improved
33. M/56 Spinocerebellar, SCLC None Spontaneous improvement
34. F/61* Bulbospinal PLEX (5) No response to PLEX. Fluctuating
course, PEG dependent
35. M/64* Myelitis, ehrlichia Steroids, PLEX (1) Resolved
38. M/59* Myeloneuropathy IVIg, rituximab (36) Worsened. Progression of symptoms
from lower to upper extremities
39. F/43 Lumbosacral polyradiculoneuropathy None Spontaneous improvement
40. M/65* Lumbosacral polyradiculoneuropathy, NHL None Worsened
F, female; IVIg, intravenous immunoglobulin; M, male; NHL, non-Hodgkin lymphoma; PLEX, plasma exchange; Pt no., patient number; URI, upper
respiratory tract infection; SCLC, small cell carcinoma.
*Evaluated at Mayo Clinic.
**Died from cancer.
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The concept of NIFs as specific immunological targets is
also supported by the higher levels of NF-L protein in CSF
of affected patients than NPH or MS controls.
The paraneoplastic patients and several others had
other underlying immunologic perturbations that may
have predisposed patients to developing neurological
autoimmunity (viz., infection [acute ehrlichosis or
chronic HIV], T-cell regulation-inhibiting monoclonal
cancer therapies, and preexisting autoimmune diseases).
HIV infection is a predisposition for autoimmunity to
develop. The pathophysiology of parainfectious NIF
autoimmunity is otherwise unknown. In the cases of can-
cer immunotherapy, the neurological syndrome was rec-
ognizable as it arose after cancer diagnosis, and was time-
locked to treatment. Neurological symptoms in the con-
text of these therapies should raise suspicion for an
autoimmune cause and broad cancer-specific neural
autoantibody profiles may assist diagnosis.12
CSF positivity was required for both sensitivity and
specificity of NIF-IgG testing. Cases were carefully ascer-
tained, utilizing strict immunohistochemical criteria and
confirmation by a trio of cell-based assays in CSF only.
CSF analytical control specimens, as required by U.S. fed-
eral regulations of clinical laboratories, were also assessed
and were universally negative by both assays, confirming
our previous findings of the high specificity of these
biomarkers in CSF for neurological autoimmunity. In
contrast, serum positivity was only detected in 26% of
our CSF-positive cases (insensitive), and was always
accompanied by a nonautoimmune diagnosis in those
who were CSF negative (nonspecific), as also previously
reported for GFAP-IgG and NMDAR-IgG.5,13-15 We also
previously demonstrated the even lower clinical specificity
of NIF-IgG testing (93%) when undertaken in serum
using a single molecular protein assay alone, such as west-
ern blot or cell-based assay.1
Various immune therapies, administered either alone or
in diverse combinations, were utilized. Three quarters of
those treated were reported to have had neurological
improvements. Among those untreated, some improved
spontaneously, while others died from cancer complications.
However, others again without cancer who remained
untreated died from neurological disease, highlighting the
importance of early immune therapy initiation in autoim-
mune neurological disorders generally. It was notable that all
three patients with encephalopathy or myelopathy had full
recoveries, either spontaneously or after immune therapies.
Limitations of this study include some missing data
from a few of the non-Mayo Clinic cases, and the retro-
spective nature of data collection. NIF autoimmune cases
appear to be rare, thus far, although we encountered
almost half of our 25-year experience since 2018, possibly
attributable to a general increase in CSF testing request
numbers, and improved NIF-IgG IFA pattern recognition
by technologists at assay screening. At present, we encoun-
ter approximately two cases per month in our laboratory,
as compared to 4 cases per week of anti-NMDA-R
encephalitis. Because all three patients we had encountered
with serum positivity where CSF was negative had non-au-
toimmune diagnoses, we also excluded another 77 histori-
cal patients for whom only serum was available to study.
NIF autoimmunity should be included in the differen-
tial diagnosis for neurological autoimmunity. Imaging
and neurophysiology confirms an array of unifocal or
multifocal neurological dysfunction spanning both central
and peripheral nervous systems. Cancer search should be
broad, although type may be predicted by IgG profile
(NF-L-IgG small cell carcinoma). A possible NF-H-IgG
association with other cancer types needs further study.
Other immunological perturbations should be considered
as potential precipitating factors (post-acute infection,
HIV, or checkpoint-inhibiting cancer therapeutics).
Although some patients die from cancer, the neurological
disorders are treatable, more often than not. Diagnosis
requires detection of 1 of 2 distinct patterns of IgG stain-
ing of neuronal intermediate filaments by indirect
immunofluorescence assay of patient CSF, and confirma-
tion by a trio of NIF-specific cell-based assays, also in
CSF. Serum testing lacks sensitivity and specificity.
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